Comparison of the efficacy of 131I versus anti-thyroid drugs in the treatment of hyperthyroidism

Not Applicable

Completed

• Conditions: Hyperthyroidism; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN10856337
• Lead Sponsor: Sun Yat-sen University (China)

Brief Summary

2009 results in https://pubmed.ncbi.nlm.nih.gov/19194213/ (added 08/04/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2007-01-31
• Study Start: 2007-12-21
• Last Update Posted: 19 April 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 460

Inclusion Criteria

1. Newly diagnosed hyperthyroid patients
2. No previous thyroid treatment
3. Elevated levels of a recent set of general serum and thyroid function tests, indication of hyperthyroidism
4. 24-hour uptake of 131I >=40%

Exclusion Criteria

1. Severe liver or kidney damage
2. Agranulocytosis
3. Pregnancy or lactation
4. Less than 8 years of age

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> The outcomes above were assessed at monthly follow-up visits during the first year and then every 3 to 6 months thereafter. Duration of follow-up was 98.4 +/- 5.5 months (range: 89 - 108 months) for participants who were included in both primary and secondary outcomes measures.<br> 1. Euthyroidism<br> 2. Persistent hyperthyroidism<br> 3. Recurrence<br> 4. Clinical hypothyroidism<br> 5. Sbclinical Hypothyroidism<br>

Secondary Outcome Measures

Name	Time	Method
<br> The outcomes above were assessed at monthly follow-up visits during the first year and then every 3 to 6 months thereafter. Duration of follow-up was 98.4 +/- 5.5 months (range: 89 - 108 months) for participants who were included in both primary and secondary outcomes measures.<br> 1. Changes in ophthalmopathy and complications<br> 2. Side effects<br> 3. Safety<br> 4. Efficacy<br>